We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

Guggenheim raised the firm’s price target on Novo Nordisk (NVO) to DKK 798 from DKK 795 and keeps a Buy rating on the shares. The firm is ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly Asia Ventures.

Britain's Terry Smith made public for the first time why Fundsmith Equity Fund dumped its Diageo stake last year.

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

Stada has lined up a new independent chairman and board of directors in a key step for the private equity-backed German drug ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s. They have helped Novo ...

At the moment, the hottest GLP-1 treatment is Ozempic. Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications including Wegovy ...